Delving into the Latest Updates on Pancreatin (Sioe Pharmaceutical) with Synapse

Overview

Basic Info

Drug Type

Enzyme

Synonyms-

Target-

Mechanism

Pancrelipase replacements

Therapeutic Areas

Other Diseases

Active Indication

Dyspepsia

Inactive Indication-

Originator Organization

SIOE Pharmaceutical Co., Ltd.

Active Organization

SIOE Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (01 Apr 1954),

Dyspepsia

Regulation-

Login to view timeline

We studied the effect of the addition of omeprazole (20 mg once a day) to treatment with pancreatin (Pancrease, Cilag, Herentals, Belgium), two or four capsules three times a day, on fecal fat excretion in a double-blind, crossover fashion in nine patients with cystic fibrosis having persistent steatorrhea while taking Pancrease, two capsules three times a day (mean fecal fat excretion, 22.3%; range, 12% to 44%). Neither doubling of the dose of Pancrease nor addition of omeprazole to the lower dose of Pancrease significantly reduced fecal fat excretion (mean, 19.6% [range, 10% to 34%]; mean, 16.4% [range, 6% to 32%], respectively). However, addition of omeprazole to the higher dose of Pancrease (four capsules three times a day) significantly reduced fecal fat excretion when compared with the two doses of Pancrease alone (mean, 10.7%; range, 4% to 25%; P less than 0.01). We conclude that adjunct therapy with omeprazole reduces fecal fat excretion in cystic fibrosis provided that a high dose of Pancrease is supplied.

01 Jan 1979·Arzneimittel-Forschung

[New evidence in therapeutic substitution of digestive enzymes (author's transl)].

Article

Author: Rupp, W ; Schleyerbach, R ; Fülberth, W ; Neubauer, H P

100 Deals associated with Pancreatin (Sioe Pharmaceutical)

Login to view more data